A Study on Waldenström’s Macroglobulinemia Demonstrates the Concrete Potential of Registry Research

A national retrospective real-world evidence (RWE) study has generated significant new insights into the epidemiology, treatment, and prognosis of the rare blood cancer Waldenström’s macroglobulinemia (WM) in Finland between 2007 and 2021. The study, published in Clinical Lymphoma, Myeloma & Leukemia, is the first of its kind conducted in Finland.

The importance of the study lies not only in its findings but also in its clear demonstration of the value of registry data, particularly in rare diseases. Because patient populations are small and geographically dispersed worldwide, conducting clinical trials is often challenging.

According to Essi Havula, Scientific Advisor at Medaffcon, the findings align well with international publications. The study did not focus on detailed treatment choices. Instead, it examined incidence, patient characteristics, overall survival, causes of death, healthcare costs, and the proportion of patients receiving treatment.

“In diseases like this, registry research is invaluable when the goal is to understand patient characteristics and clinical outcomes. Registry studies are at the core of Medaffcon’s expertise, and this research demonstrates how much can be learned about a rare cancer using existing healthcare registries. Registry research can provide highly valuable information to support decision-making and the development of care,” Havula states.

Registry Research Helps Ensure Treatments Work in Real-World Practice

Hematologist Pekka Anttila, the corresponding author in the study, also emphasizes the importance of registry data. In his view, registry data is often the only way to monitor and confirm that treatments perform as effectively in routine clinical practice as they do in clinical trials.

Registry information forms the foundation for evaluating the quality of care and planning future healthcare strategies.

“In more common diseases, registries enable comparisons between university hospital districts, for example. They allow us to assess whether treatments are delivered equitably across the country and whether outcomes are internationally comparable,” Anttila says.

He notes that particularly for new medicines, high-quality registry data can reveal both achieved benefits and previously unidentified adverse effects. This information is derived specifically from RWE studies—not solely from strictly controlled clinical drug trials.

Careful Documentation Ensures Data Quality

Anttila emphasizes that high-quality data requires careful documentation. The quality of registry research depends directly on how accurately diagnoses and clinical information are recorded. The value of accurate recording should be pinpointed already in medical education.

“Entering diagnoses into healthcare systems is not always straightforward. In diseases such as Waldenström’s macroglobulinemia and multiple myeloma, a pathological sample alone is not sufficient—clinical assessment and diagnosis by a physician are required,” Anttila explains.

According to Anttila, the next study could focus on the new drug that has recently entered the market.

“Waldenström’s macroglobulinemia is extremely rare worldwide, so progress is inevitably slow. I would wait two to three years to see how the use of new medicines develops. A new drug has recently entered the market to compete with the existing one and comparing them could be interesting. The Finnish Social Insurance Institution (Kela) registries could provide ongoing data on medication use,” he notes.

References

Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia—A Real-World Study

Read more

Find more RWE study summaries here.